Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Eur Respir J. 2018 Aug 16;52(2). pii: 1800537. doi: 10.1183/13993003.00537-2018. Print 2018 Aug.

QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study.

Author information

1
APHP, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux (CNR-MyRMA), Bactériologie-Hygiène, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France.
2
Sorbonne Université, Université Pierre et Marie Curie 06, Unité 1135, Team E13 (Bactériologie), CR7 INSERM, Centre d'Immunologie et des Maladies Infectieuses, Paris, France.
3
Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France.
4
Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.
5
Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
6
Dept of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
7
National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
8
Dept of Respiratory Medicine, Homerton University Hospital, London, UK.
9
Division of Clinical Infectious Diseases, Medical Clinic Research Center Borstel, German Center for Infection Research (DZIF), Clinical Tuberculosis Center, Borstel, Germany.
10
International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany.
11
Dept of Medicine, Karolinska Institute, Stockholm, Sweden.
PMID:
29880656
DOI:
10.1183/13993003.00537-2018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center